Differences between IGIV products: impact on clinical outcome.
about
Intravenous immunoglobulin and Alzheimer's disease: what now?Structural Characterization of Anti-Inflammatory Immunoglobulin G Fc ProteinsImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesControlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study.Comparative effectiveness of intravenous immunoglobulin for children with Kawasaki disease: a nationwide cohort study.Intravenous immunoglobulin treatment in a child with resistant atopic dermatitis.Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin GProtection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology.Special considerations with the use of intravenous immunoglobulin in older persons.The expanding role of therapeutic antibodies.Treatment of multifocal motor neuropathy with intravenous immunoglobulin.Comparative effectiveness of intravenous immunoglobulin from different manufacturing processes on Kawasaki disease.Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparationsPROTECTIVE LEVELS OF VARICELLA-ZOSTER ANTIBODY DID NOT EFFECTIVELY PREVENT CHICKENPOX IN AN X-LINKED AGAMMAGLOBULINEMIA PATIENT.Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic DermatitisDevelopment, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma.A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy.Payor issues: barriers to optimal management of patients with primary immunodeficiency.Dosing and therapy utilization: a discussion of updates on PI treatment guidelines.
P2860
Q27000371-74D10733-C95B-44C8-A44D-E923D1E2B01AQ27684721-70AB20FB-2DE0-4102-8EED-5544315C4329Q28069362-0B3AEC55-2BD8-474B-B468-F8ED8E48A9E6Q33420853-5010603E-0617-450A-924C-0C8FF95954BDQ33820448-13DA8C63-47F8-4D43-BF52-E3FC2763A9CBQ34708567-FD437318-9DBD-4182-A690-EC78B0D81B31Q35770152-0DABA9D3-C175-4B16-94E1-7B1FD6B9A358Q35803387-6AFA2944-2376-4491-A7B5-ED5DD78B040CQ36592223-10EC4A27-105F-4F8B-9939-1FF317587BB0Q36711702-7B69EA5E-FB0A-4839-BD42-2A7361F0FB26Q37931231-06BBB057-699F-4AAF-8999-380435D16BBDQ38182645-449720D5-B443-49CE-983E-13B3FD445AE2Q38202020-4EDA470E-CA53-44C8-B4AA-1C0E2886F15DQ38209742-56FF8EA2-6B7D-4246-A7C7-EE87FE86AC42Q38569717-3AB25218-9751-4DBC-8259-37DB4523A11CQ39273058-1ABC423D-9A81-42D1-9B79-07E77C6E1CE0Q40896661-0ED10C59-FF43-4B28-B4DB-40328C4404A9Q42025342-93E39311-C04B-4424-A1C8-7D1005106F97Q42119487-0154B0F9-FB02-4427-895F-688DA29D0A87Q42654125-563CE6B1-1AE6-4C42-8AA9-38C3E965F283Q43522400-42D8841D-F6C6-427A-9823-5A8DBB665E28Q46048428-481F0FE6-366F-4A9E-85B6-5981DC9CEC9B
P2860
Differences between IGIV products: impact on clinical outcome.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Differences between IGIV products: impact on clinical outcome.
@ast
Differences between IGIV products: impact on clinical outcome.
@en
type
label
Differences between IGIV products: impact on clinical outcome.
@ast
Differences between IGIV products: impact on clinical outcome.
@en
prefLabel
Differences between IGIV products: impact on clinical outcome.
@ast
Differences between IGIV products: impact on clinical outcome.
@en
P1476
Differences between IGIV products: impact on clinical outcome.
@en
P304
P356
10.1016/J.INTIMP.2005.11.003
P577
2005-12-06T00:00:00Z